Natalia Soriano-Sarabia

Dr. Natalia Soriano-Sarabia

The George Washington University, Washington D.C., USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
MSMarta Sanz
Marta Sanz
BMBrendan T. Mann
Brendan T. Mann
PRPaul L. Ryan
Paul L. Ryan
ABAlberto Bosque
Alberto Bosque
DPDaniel J. Pennington
Daniel J. Pennington
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
Under non-pathological conditions, human γδ T cells represent a small fraction of CD3+ T cells in peripheral blood (1-10%). They constitute a unique subset of T lymphocytes that recognize stress ligands or non-peptide antigens through MHC-independent presentation. Major human γδ T cell subsets, Vδ1 and Vδ2, expand in response to microbial infection or malignancy, but possess distinct tissue localization, antigen recognition, and effector responses. We hypothesized that differences at the gene, phenotypic, and functional level would provide evidence that γδ T cell subpopulations belong to distinct lineages. Comparisons between each subset and the identification of the molecular determinants that underpin their differences has been hampered by experimental challenges in obtaining sufficient numbers of purified cells. By utilizing a stringent FACS-based isolation method, we compared highly purified human Vδ1 and Vδ2 cells in terms of phenotype, gene expression profile, and functional responses. We found distinct genetic and phenotypic signatures that define functional differences in γδ T cell populations. Differences in TCR components, repertoire, and responses to calcium-dependent pathways suggest that Vδ1 and Vδ2 T cells are different lineages. These findings will facilitate further investigation into the ligand specificity and unique role of Vδ1 and Vδ2 cells in early immune responses.

21 June 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
CGCarolina Garrido
Carolina Garrido
MCMatthew L. Clohosey
Matthew L. Clohosey
CWChloe P. Whitworth
Chloe P. Whitworth
MHMichael Hudgens
Michael Hudgens
DMDavid Michael M Margolis
David Michael M Margolis
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
Current strategies aimed to cure HIV infection are based on combined efforts to reactivate the virus from latency and improve immune effector cell function to clear infected cells. These strategies are primarily focused on CD8 + T cells and approaches are challenging due to insufficient HIV antigen production from infected cells and poor HIV-specific CD8 + T cells. γδ T cells represent a unique subset of effector T cells that can traffic to tissues, and selectively target cancer or virally infected cells without requiring MHC presentation. We analyzed whether γδ T cells represent a complementary/alternative immunotherapeutic approach towards HIV cure strategies. γδ T cells from HIV-infected virologically suppressed donors were expanded with bisphosphonate pamidronate (PAM) and cells were used in autologous cellular systems ex vivo. These cells (a) are potent cytotoxic effectors able to efficiently inhibit HIV replication ex vivo, (b) degranulate in the presence of autologous infected CD4 + T cells, and (c) specifically clear latently infected cells after latency reversal with vorinostat. This is the first proof of concept to our knowledge showing that γδ T cells target and clear autologous HIV reservoirs upon latency reversal. Our results open potentially new insights into the immunotherapeutic use of γδ T cells for current interventions in HIV eradication strategies.

1 March 2014 in Cellular Immunology
Verified
Journal Article
Closed access
MLMercedes L. López
Mercedes L. López
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
GBGustavo Bruges
Gustavo Bruges
MMMaría Elena Marquez
María Elena Marquez
Klaus T. PreissnerKlaus T. Preissner
Klaus T. Preissner
HHHolger Hackstein
Holger Hackstein

24 May 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
ACAlisha Chitrakar-Hall
Alisha Chitrakar-Hall
MPMarta Sanz Perez
Marta Sanz Perez
SMSanjay Maggirwar
Sanjay Maggirwar
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
The use of antiretroviral therapy (ART) for Human Immunodeficiency Virus (HIV) treatment has been highly successful in controlling plasma viremia to undetectable levels. However, a complete cure for HIV is hindered by the presence of replication-competent HIV, integrated in the host genome, that can persist long term in a resting state called viral latency. Resting memory CD4+ T cells are considered the biggest reservoir of persistent HIV infection and are often studied exclusively as the main target for an HIV cure. However, other cell types, such as circulating monocytes and tissue-resident macrophages, can harbor integrated, replication-competent HIV. To develop a cure for HIV, focus is needed not only on the T cell compartment, but also on these myeloid reservoirs of persistent HIV infection. In this review, we summarize their importance when designing HIV cure strategies and challenges associated to their identification and specific targeting by the “shock and kill” approach.

Verified
Journal Article
Open access
PDF file
BOBrita Ostermeier
Brita Ostermeier
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
SMSanjay B. Maggirwar
Sanjay B. Maggirwar
Platelets, which are small anuclear cell fragments, play important roles in thrombosis and hemostasis, but also actively release factors that can both suppress and induce viral infections. Platelet-released factors include sCD40L, microvesicles (MVs), and alpha granules that have the capacity to exert either pro-inflammatory or anti-inflammatory effects depending on the virus. These factors are prime targets for use in extracellular vesicle (EV)-based therapy due to their ability to reduce viral infections and exert anti-inflammatory effects. While there are some studies regarding platelet microvesicle-based (PMV-based) therapy, there is still much to learn about PMVs before such therapy can be used. This review provides the background necessary to understand the roles of platelet-released factors, how these factors might be useful in PMV-based therapy, and a critical discussion of current knowledge of platelets and their role in viral diseases.

1 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
MCMatthew L. Clohosey
Matthew L. Clohosey
BMBrendan Mann
Brendan Mann
PRPaul Ryan
Paul Ryan
TATatiyana Apanasovich
Tatiyana Apanasovich
SMSanjay Maggirwar
Sanjay Maggirwar
NSNatalia Soriano-Sarabia
Natalia Soriano-Sarabia
Crosstalk between innate and adaptive pathways is a critical component to developing an effective, lasting immune response. Among natural effector cells, innate-like γδ T cells promote immunity by facilitating communication between the two compartments and exerting cytotoxic effector functions. Dysregulation of γδ T cell populations is a byproduct of primary Humanimmunodeficiency virus (HIV) infection. This is most pronounced in the depletion and loss of function within cells expressing a Vγ9Vδ2 TCR (Vδ2 cells). Whether or not prolonged viral suppression mediated by antiretroviral therapy (ART) can reverse these effects has yet to be determined. In this study, we present evidence of similar Vδ2 cell functional responses within a cohort of people living with HIV (PLWH) that has been stably suppressed for >1 year and uninfected donors. Through the use of aminobisphosphonate drugs, we were able to generate a comprehensive comparison between ex vivo and expanded Vδ2 cells within each group. Both groups had largely similar compositions of memory and effector phenotypes, post-expansion TCR repertoire diversity, and cytotoxic capabilities. Our findings support the notion that ART promotes the recovery of Vδ2 polyfunctionality and provides insight for strategies aiming to reconstitute the full immune response after infection with HIV.